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High-affinity binding sites for gastrin-releasing peptide on human
colorectal cancer tissue but not uninvolved mucosa
SR Preston, LF Woodhouse, S Jones-Blackett, GV Miller and JN Primrose
Academic Unit ofSurgery, St. James's University Hospital, Leeds LS9 7TF, UK.
S_mary Human colorectal cancer tissue and matched uninvolved mucosa from 21 patients were examined
by radioligand displacement for the presence of binding sites for bombesin-like peptides. Five cancers, but no
univolved mucosa, expressed high-affinity, low-capacity bombesin binding sites (KYd = 6.53 nM,
B.. = 58.6 fmol mg-' protein) of the gastrin-releasing peptide (GRP)-preferring subtype (IC50 4.8 nM).
Bombesin-like peptides may have a role in the pathogenesis of colorectal cancer, and bombesin receptor
antagonists may be of value in the treatment of receptor-positive tumours.
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Colorectal adenocarcinoma is the fourth most common
cancer in the world (Parkin et a!., 1988). It predominantly
affects Westernised countries, where it is the second most
common cause of cancer death, accounting for 19 000 deaths
each year in the UK, 61 000 in the USA and 85 000 in the
EU (Cancer Research Campaign Factsheets, 1993). Under-
standing of the genetic basis of colorectal carcinoma is
rapidly increasing with the discovery of the MCC (Kinzler et
al., 1991a), DCC (Fearon et al., 1990), FAP (Kinzler et al.,
1991b) and hMSH2 (Leach et al., 1993) loci. The growth of
tumours, once established genetically, may also be influenced
by local growth factors. This has been exploited in the treat-
ment of breast cancer with oestrogen antagonists (Santen et
al., 1990) and prostatic cancer with anti-androgens and
luteinising hormone-releasing hormone (LHRH) antagonists
(Gittes, 1991). The gastrointestinal tract is a very rich source
of peptide hormones, and it may be possible to affect the rate
of growth of established tumours by antagonising endo-
genous trophic hormones.
Bombesin, an amphibian tetradecapeptide, is known to
exert a wide range of effects on the mammalian gastrointes-
tinal tract, and bombesin-like immunoreactivity has been
demonstrated in the submucosal and myentenc plexuses
throughout the gut. These data led to the search for mam-
malian bombesin-like peptides and the resultant discovery of
gastrin-releasing peptide (GRP) (McDonald et al., 1979) and
neuromedin B (NMB) (Minamino et al., 1983). In the mam-
malian gut bombesin-like peptides regulate gut motility,
influence the secretion of a large number of enteric peptide
hormones and stimulate pancreatic exocrine secretion (re-
viewed in Sunday et al., 1988). To date three bombesin-like
peptide receptors have been described and cloned: the GRP-
preferring subtype (GRP receptor) (Spindel et al., 1990),
found in the gut from oesophagus to rectum (reviewed in
Sunday et al., 1988); the NMB-preferring subtype (NMB
receptor) (Wada et al., 1991), present in the oesophageal
muscularis mucosa (von Schrenck et al., 1989); and bombesin
receptor subtype 3 (BRS-3), present in the testis, uterus and
lung cancer cells, but not in the rat gastrointestinal tract
(Fathi et al., 1993). Bombesin-like peptides are recognised
mitogens potently stimulating the growth of Swiss 3T3 fibro-
blasts (Rozengurt et al., 1983) and human small-cell lung
cancer cell lines (Weber et al., 1985) and thus may be mito-
genic to receptor-bearing cells within the gut.
The aim of this present study was to examine colorectal
cancer tissue and uninvolved mucosa for bombesin family
receptors, and to characterise further any binding sites
found.
Material and methods
All materials and methods used in this study have been
previously described (Preston et al., 1993). In brief, tumour
tissue and adjacent uninvolved mucosa was collected at oper-
ation, snap frozen and stored at -70C until assayed. Bind-
ing studies were performed on membrane preparations pre-
pared from tumour and mucosa. Membrane protein was
incubated, six tubes for each point, with approximately
200pM ['5IJTyr"-BBS (Du Pont, Stevenage, UK) and un-
labelled BBS (Bachem, Saffron Walden, UK) over the con-
centration range 1 x 10-" to 1 x 106M. Scatchard analysis
was performed on the binding data. In tumours which exhib-
ited BBS binding, the binding studies were repeated, but on
this occasion the binding site was further characterised using
GRP and NMB (both Bachem) as competitors.
Results
Pathological details (Table I)
General Tissue was obtained from 12 male and nine female
patients with a median age of 68 years (range 45-77 years).
Cancer There were four caecal, three transverse colon, one
descending colon, seven sigmoid colon and six rectal
tumours, all ofwhich were histologically diagnosed as adeno-
carcinoma. The stage of the tumours varied from Dukes' B
to D.
Table I Demographic data and histology of cancer tissue
Bombesin binding
Positive Negative
Number 5 16
Median age (range) 68 (63-75) 68 (45-77)
Sex (male/female) 3/2 9/7
Site (C/AIT/D/S/R) 2/0/1/0/1/1 2/0/2/1/6/5
Stage (Dukes') (range) B-C B-D
Differentiation (good/moderate/poor) 1/3/0- 2/9/5
Tumour site: C, caecum; A, ascending; T, transverse; D,
descending; S, sigmoid; R, rectum. Tumour staging performed
according to TurnbuUl's modification of Dukes' classification (range
A-D) (Turnbull et al., 1967). 'One tumour was histologically
anaplastic, but immunohistochemical marker studies were positive
for carcinoma and negative for lymphoma.
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Figre 1 Displacement of['`5ITyr4-BBS by BBS on human colo-
rectal cancer tissue. Membrane preparations from 21 cancers
were screened for the presence of bombesin binding sites. The
results shown are means ± s.e.m. of the five tumours found to be
binding site positive. Inset: A representative Scatchard plot of the
displacement data from one assay.
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Fir 2 Standard displacenent curves for human colorectal
cancer tissue. Specifically bound ['`IjTyr4-BBS displacement by
the competitors BBS (x), GRP (U) and NMB (A) over the
concentration range I x 10-" M to I x 10-6M. Results shown
are mean (± s.e.m.) of the five colonic cancers expressing
bombesin binding sites.
Specific binding of[I25lTyr4-bombesin to hwnan colorectal
cancer and uninvolved mucosa
When examined by standard radioligand displacement assays
specific binding was demonstrated in five of the cancers
(24%) but in none of the matched uninvolved mucosa sam-
ples. The percentage ofcounts speifically bound in these five
tumours ranged from 20% to 60%. Bombesin binding to all
colon cancers defined as binding site positive was specific, to
high-affinity sites, as shown in Figure 1 [IC_0 = 7.8 (± 3.8)
nM, Kd = 6.53 (± 3.53) nM, B = 58.6 (± 34.8) fmol mg-'
protein].
Binding characteristics ofthe bombesin-like peptides to sites on
human colorectal cancer
Further displacement assays were performed on the five bind-
ing site-positive tumours using GRP and NMB as com-
petitors to the ['qTITyr4-bombesin radioligand permitting
binding site subtype determination. The relative affinities of
these peptides for the binding site were GRP, BBS >> NMB,
as can be seen in Figure 2. Full radioligand displacement was
achieved over the concentration range stated with GRP and
BBS, but 50% displacement of specific binding was only
achieved in two of the five binding site-positive tumours with
NMB. Quantitation of the affinity of the three ligands for the
colon cancers can thus be quantitated in terms of their IC5o
values [mean (± s.e.m. of the five binding site positive
cancers; GRP [4.8 (± 0.9) nMJ, BBS [7.8 (± 3.8) nM] and
NMB (>lOOOnM).
Bombesin-like receptors have been previously demonstrated
on the mouse colon cancer cell line MC26. In this line
bombesin stimulated growth when assayed by [3H}thymidine
incorporation and MTT assays (Narayan et al., 1990).
Inhibition of growth of the human colon cancer cell line
HT29 by the bombesin antagonist RC-3095 has also been
demonstrated using a nude mouse xenograft model (Radu-
lovic et al., 1991). The same group also discovered that 40%
of human colorectal cancers expressed bombesin binding sites
but that none of the matched mucosa were binding site
positive (Radulovic et al., 1992). In this study we have
substantiated the evidence that a percentage of human colo-
rectal cancers, 24% in our study, express binding sites for
bombesin-like peptides not expressed on matched uninvolved
colorectal mucosa. In addition, we have made the novel
observation that these binding sites are of the GRP-pre-
ferring subtype.
Neoplastic cells from both breast (Giacchetti et al., 1990)
and stomach (Preston et al., 1993) have also been shown to
express binding sites for GRP, not expressed by non-neo-
plastic epithelial cells. It appears that the expression of these
receptors is a feature of neoplastic transformation and thus
may be implicated in the local tissue regulation of tumour
growth.
The finding that the binding sites expressed by the colorec-
tal cancers are of the GRP-preferring subtype is important,
as GRP is the bombesin-like peptide naturally occurring in
the submucosal and myentenrc plexuses of the human colon,
where it may stimulate the growth of cancer cells in a para-
crne manner. There are, however, other mechanisms by
which bombesin-like peptides may stimulate cancer cell
growth. GRP is known to affect the secretion of a number of
gut peptides (Sunday et al., 1988) and may thus indirectly
stimulate cell growth and division. In addition, all of the
currently available, stable, bombesin antagonists are specific
for the GRP-preferring bombesin receptor and are thus suit-
able for further investigation into their effects on these bind-
ing site-positive tumours.
At present we may only speculate as to the significance of
GRP binding site expression on human colorectal cancer
cells, but the expression of these receptors on cancerous cells
but not on normal epithelium is becoming a widely described
phenomenon (Giacchetti et al., 1990; Radulovic et al., 1991;
Preston et al., 1993) and certainly warrants further study.
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